Table 2.
Role of pretherapeutic determination of Pgp activity.
| Variables |
Therapy cycle |
B/A and controls |
|||
|
H pylori positive |
H pylorinegative |
||||
| 1 = A (n = 20) | 2 or more = B (n = 33) | NO (n = 12) | Pa | Beta Pb | |
| Age (yr) | 47.5±8.8 | 47.3±13.7 | 48.3±16.5 | 0.973 | 0.152 |
| Sex (M/ F) | 9/11 | 15/18 | 5/7 | 0.975 | 0.153 |
| DHP | 2.75±0.91 | 2.90±0.97 | 1.0±0.0 | 0.00001 | 0.00065 |
| DIEn | 2.65±0.81 | 3.06±0.86 | 1.0±0.0 | 0.00001 | 0.45 |
| RMF (mean±SD) | 0.889±0.28 | 1.647±0.65 | 0.787±0.29 | 0.00001 | 0.000005 |
H pylori positive patients: A = one therapy cycle, B = two or more therapy cycles; NO = no therapy, M = male; F = female; DHP = H pylori density; DIEn = density of intraepithelial neutrophil infiltration; RMF = ratio of mean fluorescences, Pa for analysis of variance, Pb for multiple regression analysis.